Ah Equity Partners Bio Ii, L.L Sells 5,000,000 Shares of Nautilus Biotechnology (NASDAQ:NAUT) Stock

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) major shareholder Ah Equity Partners Bio Ii, L.L sold 5,000,000 shares of Nautilus Biotechnology stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $2.35, for a total transaction of $11,750,000.00. Following the completion of the sale, the insider owned 971,885 shares in the company, valued at approximately $2,283,929.75. This trade represents a 83.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Nautilus Biotechnology Trading Up 3.9%

NASDAQ NAUT traded up $0.10 during trading on Thursday, hitting $2.68. The company had a trading volume of 300,368 shares, compared to its average volume of 311,885. The company’s fifty day moving average is $2.92 and its 200-day moving average is $2.45. Nautilus Biotechnology, Inc. has a one year low of $0.62 and a one year high of $4.31. The company has a market cap of $340.57 million, a price-to-earnings ratio of -5.83 and a beta of 0.75.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its earnings results on Tuesday, April 28th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of NAUT. Sentinel Trust Co. LBA purchased a new position in Nautilus Biotechnology during the 4th quarter valued at about $1,462,000. Corient Private Wealth LLC grew its holdings in Nautilus Biotechnology by 860.0% in the second quarter. Corient Private Wealth LLC now owns 435,350 shares of the company’s stock worth $316,000 after purchasing an additional 390,000 shares during the period. Jacobs Levy Equity Management Inc. bought a new position in shares of Nautilus Biotechnology during the first quarter valued at approximately $194,000. Jane Street Group LLC increased its stake in shares of Nautilus Biotechnology by 304.1% during the second quarter. Jane Street Group LLC now owns 290,369 shares of the company’s stock valued at $210,000 after purchasing an additional 218,512 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Nautilus Biotechnology by 152.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 297,437 shares of the company’s stock valued at $580,000 after purchasing an additional 179,721 shares during the last quarter. 50.71% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on NAUT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nautilus Biotechnology in a research report on Tuesday, April 21st. Guggenheim raised their target price on Nautilus Biotechnology from $2.50 to $4.00 and gave the company a “buy” rating in a research note on Friday, February 27th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $4.00.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.